Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma
Latest Information Update: 09 Feb 2024
At a glance
- Drugs BNT 113 (Primary)
- Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HARE-40
- 02 Feb 2024 Status changed from active, no longer recruiting to completed.
- 02 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 Sep 2023 Status changed from suspended to active, no longer recruiting.